Company research
GLAUKOS Corp
CIK 1192448Updated Sep 29, 2026
SecurityGKOS · NYSE · equity
GKOS price & chart
Loading TradingView…
NYSE:GKOS on TradingView ↗About the company
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
In the news
Recent filings
144 filing
144 filing
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 893,487,000Source | 974,756,000Source | 940,414,000Source | 1,002,383,000Source |
| Property, Plant and Equipment, NetUSD | 113,253,000Source | 97,867,000Source | 103,212,000Source | 94,403,000Source |
| GoodwillUSD | 66,710,000Source | 66,134,000Source | 66,134,000Source | 66,134,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 141,916,000Source | 263,445,000Source | 282,956,000Source | 307,869,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 90,813,000Source | 169,626,000Source | 93,467,000Source | 119,525,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 108,608,000Source | 60,744,000Source | 39,850,000Source | 36,073,000Source |
| Inventory, NetUSD | 63,564,000Source | 57,678,000Source | 41,986,000Source | 37,841,000Source |
| Assets, CurrentUSD | 474,984,000Source | 449,792,000Source | 395,461,000Source | 443,859,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 24,052,000Source | 12,455,000Source | 18,194,000Source | 17,250,000Source |
| Operating Lease, Right-of-Use AssetUSD | 31,527,000Source | 30,254,000Source | 27,146,000Source | 25,826,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 237,332,000Source | 207,825,000Source | 478,648,000Source | 472,378,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 58,000Source | 56,000Source | 49,000Source | 48,000Source |
| Retained Earnings (Accumulated Deficit)USD | -933,130,000Source | -745,439,000Source | -599,067,000Source | -464,406,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 3,303,000Source | 2,615,000Source | 1,165,000Source | -2,975,000Source |
| Stockholders' Equity Attributable to ParentUSD | 656,155,000Source | 766,931,000Source | 461,766,000Source | 530,005,000Source |
| Additional Paid in Capital, Common StockUSD | 1,586,056,000Source | 1,509,831,000Source | 1,059,751,000Source | 997,470,000Source |
| Liabilities and EquityUSD | 893,487,000Source | 974,756,000Source | 940,414,000Source | 1,002,383,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 101,275,000Source | 75,125,000Source | 74,014,000Source | 72,359,000Source |
| Operating Lease, Liability, CurrentUSD | 1,314,000Source | 1,353,000Source | 1,309,000Source | 430,000Source |
| Accounts Payable, CurrentUSD | 24,624,000Source | 13,026,000Source | 13,440,000Source | 14,403,000Source |
| Operating Lease, Liability, NoncurrentUSD | 35,767,000Source | 33,936,000Source | 30,427,000Source | 28,905,000Source |
| Deferred Income Tax Liabilities, NetUSD | 441,000Source | 6,928,000Source | 7,144,000Source | 7,264,000Source |
| Other Liabilities, NoncurrentUSD | 31,740,000Source | 22,373,000Source | 13,752,000Source | 10,278,000Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | 108,608,000Source | 60,744,000Source | 39,850,000Source | 36,073,000Source |
| Accrued Liabilities, CurrentUSD | 76,651,000Source | 62,099,000Source | 60,574,000Source | 57,956,000Source |
| Deferred Tax Liabilities, NetUSD | 441,000Source | 6,928,000Source | 7,144,000Source | 7,264,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -187,691,000Source | -146,372,000Source | -134,661,000Source | -99,195,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 38,093,000Source | 35,650,000Source | 33,654,000Source | 31,576,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 63,218,000Source | 50,207,000Source | 43,528,000Source | 38,561,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 53,020,000Source | 21,966,000Source | 3,843,000Source | 3,138,000Source |
| Increase (Decrease) in InventoriesUSD | 7,702,000Source | 18,788,000Source | 4,830,000Source | 15,472,000Source |
| Deferred Income Tax Expense (Benefit)USD | -6,487,000Source | -216,000Source | -120,000Source | -55,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -14,789,000Source | -61,318,000Source | -57,758,000Source | -33,083,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 12,437,000Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -77,613,000Source | 47,831,000Source | 14,095,000Source | 44,779,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 7,666,000Source | 6,300,000Source | 20,248,000Source | 30,265,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 8,132,000Source | 6,563,000Source | 3,273,000Source | 2,730,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 11,886,000Source | 91,540,000Source | 15,042,000Source | 6,251,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -79,712,000Source | 75,036,000Source | -27,280,000Source | 16,479,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 94,647,000Source | 174,359,000Source | 99,323,000Source | 126,603,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,212,000Source | 4,466,000Source | 4,348,000Source | 4,434,000Source |
| Income Taxes Paid, NetUSD | 949,000Source | 1,360,000Source | 1,557,000Source | 522,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 63,218,000Source | 50,207,000Source | 43,528,000Source | 38,561,000Source |
| Amortization of Intangible AssetsUSD | 27,128,000Source | 24,701,000Source | 24,912,000Source | 24,912,000Source |
| DepreciationUSD | 10,965,000Source | 10,949,000Source | 8,742,000Source | 6,664,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 1,216,000Source | -4,620,000Source | 980,000Source | -2,242,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -32,000Source | -598,000Source | -893,000Source | 24,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 30,000,000Source |
| GoodwillUSD | 66,710,000Source | 66,134,000Source | 66,134,000Source | 66,134,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 112,867,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | -5,351,000Source | 771,000Source | 934,000Source | 766,000Source |
| Induced Conversion of Convertible Debt ExpenseUSD | — | 18,012,000Source | — | — |
| InterestExpenseNonoperatingUSD | 4,635,000Source | 10,040,000Source | — | — |
| Inventory Write-downUSD | 2,645,000Source | 4,449,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -187,691,000Source | -146,372,000Source | -134,661,000Source | -99,195,000Source |
| Nonoperating Income (Expense)USD | 6,558,000Source | -23,235,000Source | -5,027,000Source | -16,116,000Source |
| Operating ExpensesUSD | 482,361,000Source | 411,820,000Source | 367,836,000Source | 296,196,000Source |
| Other Nonoperating Income (Expense)USD | 479,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 13,453,000Source | 39,347,000Source | 12,748,000Source | 3,577,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 507,442,000Source | 383,481,000Source | 314,711,000Source | 282,862,000Source |
| Cost of RevenueUSD | 111,814,000Source | 94,027,000Source | 75,575,000Source | 68,979,000Source |
| Selling, General and Administrative ExpenseUSD | 331,747,000Source | 261,166,000Source | 224,068,000Source | 192,925,000Source |
| Operating Income (Loss)USD | -199,600,000Source | -122,366,000Source | -128,700,000Source | -82,313,000Source |
| Other Nonoperating Income (Expense)USD | 479,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -193,042,000Source | -145,601,000Source | -133,727,000Source | -98,429,000Source |
| Income Tax Expense (Benefit)USD | -5,351,000Source | 771,000Source | 934,000Source | 766,000Source |
| Net Income (Loss) Attributable to ParentUSD | -187,691,000Source | -146,372,000Source | -134,661,000Source | -99,195,000Source |
| Earnings Per Share, BasicUSD per share | -3.28Source | -2.77Source | -2.78Source | -2.09Source |
| Earnings Per Share, DilutedUSD per share | -3.28Source | -2.77Source | -2.78Source | -2.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 57,190,000Source | 52,755,000Source | 48,433,000Source | 47,444,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 57,190,000Source | 52,755,000Source | 48,433,000Source | 47,444,000Source |
| Interest Expense (non-operating)USD | 4,635,000Source | 10,040,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 27,128,000Source | 24,701,000Source | 24,912,000Source | 24,912,000Source |
| Current Income Tax Expense (Benefit)USD | 1,136,000Source | 987,000Source | 1,054,000Source | 821,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 30,000,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 282,761,000Source | 289,454,000Source | 239,136,000Source | 213,883,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -197,636,000Source | -147,828,000Source | -138,205,000Source | -101,316,000Source |
| Interest and Other IncomeUSD | 10,714,000Source | 11,105,000Source | 9,164,000Source | 2,375,000Source |
| Interest ExpenseUSD | — | — | 13,633,000Source | 13,720,000Source |
| Nonoperating Income (Expense)USD | 6,558,000Source | -23,235,000Source | -5,027,000Source | -16,116,000Source |
| Operating ExpensesUSD | 482,361,000Source | 411,820,000Source | 367,836,000Source | 296,196,000Source |
Filing attachments
gkos-ex99_1.htm · 8-K · 2026-08-03
EX-99.1 2 gkos-ex99_1.htm EX-99.1 Investor Presentation AUGUST 2026 Exhibit 99.1 Logo Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forw…
Read attachment ↗gkos-ex99_1.htm · 8-K · 2026-07-29
EX-99.1 2 gkos-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs clewis@glaukos.com Glaukos Announces Second Quarter 2026 Financial Results Aliso Viejo, CA - July 29, 2026 - Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial resul…
Read attachment ↗gkos-ex99_2.htm · 8-K · 2026-07-29
EX-99.2 3 gkos-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 JULY 29, 2026 ───────────────── GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Looking Statements” and “Statement Regarding U…
Read attachment ↗d135093dex991.htm · 8-K · 2026-05-04
EX-99.1 2 d135093dex991.htm EX-99.1 EX-99.1 Investor Presentation MAY 2026 Exhibit 99.1 Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for f…
Read attachment ↗gkos-ex99_1.htm · 8-K · 2026-04-29
EX-99.1 2 gkos-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Chris Lewis Vice President, Investor Relations & Corporate Affairs clewis@glaukos.com Glaukos Announces First Quarter 2026 Financial Results Aliso Viejo, CA - April 29, 2026 - Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results…
Read attachment ↗gkos-ex99_2.htm · 8-K · 2026-04-29
EX-99.2 3 gkos-ex99_2.htm EX-99.2 EX-99.2 APRIL 29, 2026 ────────────────── Exhibit 99.2 GLAUKOS CORPORATION (NYSE: GKOS) FIRST QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook. Please see “Forward-Looking Statements” and “Statement Regarding …
Read attachment ↗